ADMA Biologics, Inc. (ADMA) Stock Price

ADMAStock

$9.34−46.26%52W

Market Cap$2.09B

P/E14.34x

PEG Ratio—

Div yield—

Beta0.72

ADMA Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-51.75%

Price vs S&P 500 (4W)5.32%

VGM Score51.94

P/E Ratio (Annual)14.34x

P/CF (Annual)41.82x

Book Value / Share (Quarterly)$1.81

P/TBV (Annual)9.11x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)49.04%

Cash Flow / Share (Quarterly)$0.52

Price vs S&P 500 (YTD)-61.62%

Gross Margin (TTM)64.71%

Net Profit Margin (TTM)32.98%

EPS (TTM)$0.71

10-Day Avg Trading Volume1.74M

EPS Excl Extra (TTM)$0.71

Revenue Growth (5Y)64.62%

EPS (Annual)$0.60

ROI (Annual)26.74%

Gross Margin (Annual)57.39%

Net Profit Margin (5Y Avg)-13.41%

Cash / Share (Quarterly)$0.60

P/E Basic Excl Extra (TTM)12.47x

Revenue Growth QoQ (YoY)1.98%

P/E Normalized (Annual)14.34x

ROA (Last FY)23.54%

Revenue Growth TTM (YoY)8.04%

EBITD / Share (TTM)$0.93

ROE (5Y Avg)-5.51%

Operating Margin (TTM)43.40%

Cash Flow / Share (Annual)$0.12

P/B Ratio5.16x

P/B Ratio (Quarterly)4.75x

Net Income / Employee (Annual)$227,100

EV / Revenue (TTM)4.23x

Net Interest Coverage (TTM)35.86x

ROA (TTM)26.58%

EPS Growth QoQ (YoY)19.33%

EV / EBITDA (TTM)9.74x

EPS Incl Extra (Annual)$0.60

Current Ratio (Annual)6.71x

Quick Ratio (Quarterly)3.62x

3-Month Avg Trading Volume3.86M

52-Week Price Return-46.26%

EV / Free Cash Flow (Annual)78.83x

P/E Incl Extra (TTM)12.47x

Revenue / Employee (TTM)$791,800

Tangible BV / Share (Quarterly)$1.81

P/S Ratio (Annual)4.13x

Asset Turnover (Annual)0.82x

52-Week High$20.46

Operating Margin (5Y Avg)-6.93%

EPS Excl Extra (Annual)$0.60

CapEx CAGR (5Y)12.45%

Tangible BV CAGR (5Y)40.88%

26-Week Price Return-39.82%

Quick Ratio (Annual)3.63x

13-Week Price Return17.78%

Total Debt / Equity (Annual)0.15x

Current Ratio (Quarterly)6.97x

Enterprise Value$2.17B

Revenue / Share Growth (5Y)33.56%

Asset Turnover (TTM)0.81x

Book Value / Share Growth (5Y)18.97%

Revenue / Employee (Annual)$788,500

Inventory Turnover (Annual)1.15x

Pretax Margin (Annual)35.80%

Cash / Share (Annual)$0.37

3-Month Return Std Dev38.33%

Gross Margin (5Y Avg)33.70%

Net Income / Employee (TTM)$261,100

ROE (Last FY)30.78%

Net Interest Coverage (Annual)35.46x

EPS Basic Excl Extra (Annual)$0.60

P/FCF (TTM)17.97x

Receivables Turnover (TTM)4.13x

EV / Free Cash Flow (TTM)18.66x

Total Debt / Equity (Quarterly)0.48x

EPS Incl Extra (TTM)$0.71

Receivables Turnover (Annual)4.90x

ROI (TTM)30.10%

P/S Ratio (TTM)4.11x

Pretax Margin (5Y Avg)-15.38%

Revenue / Share (Annual)$2.08

Tangible BV / Share (Annual)$2.00

Forward P/E9.27x

Price vs S&P 500 (52W)-64.82%

P/E Ratio (TTM)12.47x

EPS Growth TTM (YoY)-16.60%

Year-to-Date Return-48.79%

5-Day Price Return-2.20%

EPS Normalized (Annual)$0.60

ROA (5Y Avg)2.12%

Net Profit Margin (Annual)28.80%

Month-to-Date Return10.40%

Cash Flow / Share (TTM)$-0.07

EBITD / Share (Annual)$0.77

Operating Margin (Annual)36.87%

LT Debt / Equity (Annual)0.15x

P/CF (TTM)15.42x

ROI (5Y Avg)2.07%

P/E Excl Extra (TTM)12.47x

LT Debt / Equity (Quarterly)0.47x

EPS Basic Excl Extra (TTM)$0.71

P/TBV (Quarterly)4.76x

P/B Ratio (Annual)9.09x

Inventory Turnover (TTM)0.84x

Pretax Margin (TTM)42.26%

Book Value / Share (Annual)$2.01

Price vs S&P 500 (13W)15.83%

Beta0.72x

P/FCF (Annual)76.63x

Revenue / Share (TTM)$2.22

ROE (TTM)39.59%

52-Week Low$7.21

vGradeC

gGradeC

mGradeC

vgmGradeC

ADMA Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 5, 2026	$0.16	$0.17	+3.53%(+$0.01)
Q1 2026	May 6, 2026	$0.20	$0.17	-15.25%(-$0.03)
Q4 2025	Feb 25, 2026	$0.20	$0.22	+7.85%(+$0.02)
Q3 2025	Nov 5, 2025	$0.15	$0.16	+2.59%(+$0.00)
Q2 2025	Aug 6, 2025	$0.14	$0.14	+7.41%(+$0.01)

ADMA Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.00

Industry Peers — Biological Products(183)

Symbol	Value Score	Growth Score	Momentum Score	Price
ADMAADMA Biologics, Inc.	C	C	C	$9.34
AMGNAmgen Inc	C	C	B	$432.42
GILDGilead Sciences Inc	C	B	B	$145.68
ARGXargenx SE American Depositary Shares	D	A	B	$1023.21
MRNAModerna, Inc. Common Stock	D	C	A	$137.99
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$207.88
BIIBBiogen Inc. Common Stock	C	D	B	$218.50
BNTXBioNTech SE American Depositary Share	C	C	C	$102.08
NBIXNeurocrine Biosciences Inc	C	B	C	$154.06
EXELExelixis Inc	C	B	B	$54.45
HALOHalozyme Therapeutics, Inc.	C	B	B	$105.35
TECHBio-Techne Corp.	D	C	B	$72.35
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	$351.46
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	$134.97
RGENRepligen Corp	D	C	B	$176.27
KYMRKymera Therapeutics, Inc. Common Stock	D	B	B	$118.15
PCVXVaxcyte, Inc. Common Stock	—	—	B	$59.84
QGENQIAGEN N.V.	C	C	B	$43.11
TWSTTwist Bioscience Corporation Common Stock	D	B	A	$141.38
IBRXImmunityBio, Inc. Common Stock	F	A	B	$8.05
IMVTImmunovant, Inc. Common Stock	—	—	B	$41.20
SRRKScholar Rock Holding Corporation Common Stock	F	—	B	$57.80
CGONCG Oncology, Inc. Common stock	F	A	B	$74.34
CRSPCRISPR Therapeutics AG	D	B	C	$57.72
RLAYRelay Therapeutics, Inc. Common Stock	F	D	B	$18.77
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	A	$25.19
DNLIDenali Therapeutics Inc. Common Stock	F	—	B	$24.00
IOVAIovance Biotherapeutics, Inc. Common Stock	C	B	A	$8.01
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	$71.76
BEAMBeam Therapeutics Inc. Common Stock	C	B	B	$29.32
BCRXBioCryst Pharmaceuticals Inc	B	A	B	$9.82
KODKodiak Sciences Inc Common Stock	—	—	B	$37.72
MESOMesoblast Limited American Depositary Shares	D	B	B	$17.44
VCELVericel Corporation	D	B	B	$40.95
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	B	$44.84
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	$36.62
TSHATaysha Gene Therapies, Inc. Common Stock	F	B	B	$5.77
VIRVir Biotechnology, Inc. Common Stock	B	B	B	$10.83
INBXInhibrx Biosciences, Inc. Common Stock	D	C	A	$123.41
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	$3.34
ALVOAlvotech Ordinary Shares	C	D	C	$4.95
NVAXNovavax Inc	B	D	C	$9.26
MAZEMaze Therapeutics, Inc. Common Stock	—	—	C	$27.44
SLBTSL Science Holding Limited Ordinary Shares	—	—	C	$2.70
REPLReplimune Group, Inc.	—	—	A	$15.50
IMTXImmatics N.V. Ordinary Shares	C	D	C	$9.45
VORVor Biopharma Inc. Common Stock	—	—	B	$22.65
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	A	$21.70
MGTXMeiraGTx Holdings plc Ordinary Shares	D	C	B	$13.82
SANASana Biotechnology, Inc. Common Stock	—	—	B	$3.93
ODTXOdyssey Therapeutics, Inc. Common Stock	—	C	B	$24.36

About ADMA Biologics, Inc.

ADMA Biologics manufactures and markets plasma-derived immunoglobulin (IG) and intravenous immunoglobulin (IVIG) products for immunodeficient patients and those at risk for infectious diseases. The company operates through ADMA BioManufacturing, its primary revenue source, and Plasma Collection Centers, supplemented by laboratory and contract manufacturing services. It also sells plasma-derived intermediate fractions generated from its FDA-approved manufacturing process. The company derives substantially all revenue from the United States market.